161 related articles for article (PubMed ID: 11758682)
1. Renal disease in Fabry patients.
Grünfeld JP; Lidove O; Joly D; Barbey F
J Inherit Metab Dis; 2001; 24 Suppl 2():71-4; discussion 65. PubMed ID: 11758682
[TBL] [Abstract][Full Text] [Related]
2. Renal pathological changes in Fabry disease.
Sessa A; Meroni M; Battini G; Maglio A; Brambilla PL; Bertella M; Nebuloni M; Pallotti F; Giordano F; Bertagnolio B; Tosoni A
J Inherit Metab Dis; 2001; 24 Suppl 2():66-70; discussion 65. PubMed ID: 11758681
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
4. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
5. [Renal lesions in patients with Fabry's disease].
Gubler MC
Rev Med Interne; 2010 Dec; 31 Suppl 2():S220-5. PubMed ID: 21211668
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.
Desnick RJ; Wasserstein MP; Banikazemi M
Contrib Nephrol; 2001; (136):174-92. PubMed ID: 11688379
[No Abstract] [Full Text] [Related]
7. Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure.
Van Loo A; Vanholder R; Madsen K; Praet M; Kint J; De Paepe A; Messiaen L; Lameire N; Hasholt L; Sørensen SA; Ringoir S
Am J Nephrol; 1996; 16(4):352-7. PubMed ID: 8739292
[TBL] [Abstract][Full Text] [Related]
8. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.
Branton MH; Schiffmann R; Sabnis SG; Murray GJ; Quirk JM; Altarescu G; Goldfarb L; Brady RO; Balow JE; Austin Iii HA; Kopp JB
Medicine (Baltimore); 2002 Mar; 81(2):122-38. PubMed ID: 11889412
[No Abstract] [Full Text] [Related]
9. Renal transplantation in patients with Fabry disease.
Sessa A; Meroni M; Battini G; Maglio A; Nebuloni M; Tosoni A; Panichi V; Bertagnolio B
Nephron; 2002 Jun; 91(2):348-51. PubMed ID: 12053080
[TBL] [Abstract][Full Text] [Related]
10. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes.
Glass RB; Astrin KH; Norton KI; Parsons R; Eng CM; Banikazemi M; Desnick RJ
J Comput Assist Tomogr; 2004; 28(2):158-68. PubMed ID: 15091117
[TBL] [Abstract][Full Text] [Related]
12. Natural history of Fabry disease in males: preliminary observations.
Schiffmann R
J Inherit Metab Dis; 2001; 24 Suppl 2():15-7; discussion 11-2. PubMed ID: 11758674
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
14. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
15. Long-term Outcomes of Kidney Transplantation in Fabry Disease.
Ersözlü S; Desnick RJ; Huynh-Do U; Canaan-Kühl S; Barbey F; Genitsch V; Mueller TF; Cheetham M; Flammer AJ; Schaub S; Nowak A
Transplantation; 2018 Nov; 102(11):1924-1933. PubMed ID: 29688992
[TBL] [Abstract][Full Text] [Related]
16. [Fabry disease. Clinical and genetic aspects. Therapeutic perspectives].
Germain DP
Rev Med Interne; 2000 Dec; 21(12):1086-103. PubMed ID: 11191676
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
18. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
